This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
To describe the current status regarding the duration of adjuvant tamoxifen and/or aromatase inhibitors in women with early-stage hormone receptor positive breast cancer. Recent findings Women with early-stage breast cancers that express estrogen and/or progesterone receptors benefit from adjuvant hormonal therapy with antiestrogen drugs, researchers in the United States report.
We care about your feedback. Let us know how we can improve your CancerCompass experience.